Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus-based immunosuppression for cardiovascular risk after kidney transplant
ACTRN12610000320055Phase 4Not yet recruiting
- Sponsor
- Department of Health
- Start
- May 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of everolimus and cyclosporine in cardiac morbidity and kidney transplant immunosuppression (2 arms), sponsored by Department of Health. Primary endpoint: Vascular function. Planned start May 2010; status: not yet recruiting.
02
Drugs
everolimuscyclosporine
03
Conditions
cardiac morbiditykidney transplant immunosuppression
Beyond the preview
Go deeper on ACTRN12610000320055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000320055.